Back to EZorb Newsletter Index

 

EZorb

  

EZORB MONTHLY NEWSLETTER NOV 28, 2014

In this issue:

 

1. Share Success: Letters From Readers
2. Research News: Irregular Heart Beat Poses Risk in Pulmonary Hypertension Patients
3. Useful Links
4. Calcium Absorption Test
5. What Are Others Saying About EZorb and Marvlix?
  

1. Share Success: Letters From Readers 

***************************************************

Letter I: From Loretta M

Received at Testimonial Submit Form on Wednesday, October 15, 2014 at 18:01:26

(Unedited)

 

Hi, my name is Loretta M. I have been taking EZorb for a year now, it has not cause me any trouble.

I sleep well, and now I took the bone density , the osteoporosis did not disappear, but did get better in some areas. I did expect a better result, but I finished 3-bottles and drop off for a while to rest my body.

Every thing, takes Time & wisdom, I have no side effect, I am doing well. I rather to take EZorb, than something else that has the side effect. Every person's body works differently, so I tried it, it is slow for me, but I have no side effect! So I just order 3 more bottles!


Letter II: From Corine M., Houston, TX, US

Received at Testimonial Submit Form on Friday, June 20, 2014 at 22:05:01

(Unedited)

 

Hi, my name is Corine M. I was suffering from a bone spur about three years ago. I went on line searching for a herb that would perhaps relieve my pain because the doctor wanted to do surgery.

I saw a letter from a brother whose sister told him about EZorb because he was having so much trouble with his bone spur he could not wear shoes. His testimony sold me on EZorb. I ordered 3 bottles and begin to use as directed.

After the first bottle I could see results. The bone spur went away after completing two and a half bottles. I continued to use EZorb because I saw that it was helping my muscles and bones. I use to have pains in the lower part of my back because of a car accident. After I continue to use EZorb and cutting down the amount I was using it eliminated the back pain.

This is my third year using EZorb and I will continue to use it for my bones and muscles. I can't thank you enough for EZorb.

CMerritt/ Houston, TX


Letter III: From Carol D.

  

Received at sharesucess@ezorbonline.com on Thursday, June 12, 2014 1:45 PM

(Unedited)

 

Hi Medical Staff,

I have been faithfully taking 6 capsules of the Marvlix a day three in the morning and twelve hours later three more. I have been feeling better.

Today I actually read three pages of small print in a book I have. This was unheard of for me I used my glasses but usually I have to use a magnifying glass along with the glasses.

My nails are shining and looking better. I am sleeping more at night and not running to the bathroom to urinate as much.

I've been telling some of my friends about your product. I am convinced your product is good for me. My brain feels better. I am amazed at my increase in sight to the point I could read three pages of small print. This was unheard of for the last two years.

Carol D.


***************************************************

From the Desk of EZorb Newsletter Editor:

 
This newsletter is now read by over 70,000 subscribers worldwide. Success stories you have contributed over the years have had a great impact on many people's quality of life. Your continuous support will be greatly appreciated by tens of thousands who have been suffering and would continuously suffer, without your help! Please email your story to sharesuccess@ezorbonline.com or simply post it at Testimonial Submit Form. Your personal information will never be revealed to the public.


2. Research News: Irregular Heart Beat Poses Risk in Pulmonary Hypertension Patients

 

Supraventricular arrhythmias (SVAs) are common and usually cause clinical deterioration in patients with idiopathic pulmonary arterial hypertension (IPAH), a study shows.

Persistent SVAs were associated with an increased mortality risk, whereas successful treatment led to clinical recovery, the researchers report in the American Journal of Cardiology.

"These findings support that restoration and maintenance of sinus rhythm are important treatment goal[s] in IPAH patients", write Zhi-Cheng Jing (Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing) and co-authors.

The prospective, multicentre study involved 280 IPAH patients, aged an average of 39 years, of whom 40 had at least one SVA during an average 31 months of follow-up, giving a 6-year cumulative incidence of 15.8%.

Survival was significantly poorer in patients who developed SVAs than those who did not, with 1-year rates of 85% versus 92% and 6-year rates of 53% versus 75%. However, the survival disadvantage was confined to patients with persistent arrhythmia, which increased mortality risk nearly fivefold after accounting for potential confounders. By contrast, the survival of patients with transient SVAs was not significantly different to that of those without arrhythmias.

The most common SVAs were atrial fibrillation, flutter and tachycardia. Treatment successfully restored sinus rhythm in all cases of atrial tachycardia, but less than half of atrial flutter cases and only a quarter of atrial fibrillation cases.

Jing et al note that most patients with SVAs had marked clinical deterioration or worsening heart failure, with the most common signs being increasing dyspnoea on exertion, palpitations and fluid retention with leg oedema. However, one patient was asymptomatic at the time of diagnosis.

Also, the researchers found that markers of heart enlargement (increased right ventricular diameter and left atrial area) significantly increased the likelihood of patients developing an SVA, as did increased mean right atrial pressure and pulmonary vascular resistance.

"Thus, electrocardiogram (even Holter monitor), echocardiography and right heart catheterization should be part of our routine assessment for PAH patients", concludes the team.

Original research was published in Am J Cardiol 2014; Advance online publication.


3. Useful Links

Frequently Asked Questions & Answers

EZorb Clinical Studies

Marvlix Benefits

Order Now

  

 

4. Calcium Absorption Test

EZorb Calcium has set a new world record of absorption rate. You can compare EZorb with other calcium supplements by using the simple step-by-step instructions we provide. E-mail your request to test@elixirindustry.com for a copy of the instructions.

 

 

5. What Are Others Saying About EZorb and Marvlix?

EZorb and Marvlix have restored confidence in thousands of men and women. It has brought happiness and healthy life to families around the world. Click here to read what people say about EZorb and Marvlix.

Back to EZorb Newsletter Index

 
 
  Copyright 2014 Elixir Industry